Biotechnology
CATX Showcases Breakthroughs in Radiopharmaceutical Development at Oppenheimer Summit
Targeted radiopharmaceuticals promising multiple catalysts and clinical advancements heading into 2024 CATX (CATX), a company pioneering targeted radiopharmaceutical therapies, provided...
OnKure Positioned for Success with PI3Kα Inhibitor OKI-219 in Breast Cancer
Targeting H1047R Mutations for Improved Efficacy and Reduced Toxicity in an Expanding Market OnKure Therapeutics (OKUR) is making waves in...
VKTX Set to Showcase Promising Higher-Dose Data for Oral VK2735 at ObesityWeek
Potential Upside in Obesity Treatment as Higher Dose Efficacy Data Expected to Boost Competitive Profile Viking Therapeutics (VKTX) is gearing...
Emerging Therapeutic Developments: TYRA, RVMD, IDYA, and More Poised for Key Data Releases
Major trials signal potential advancements in cancer treatment and rare disease therapies Biotech companies are preparing for significant milestones as...
Larimar Therapeutics Poised for Growth with Nomlabofusp: Target Price Set at $22
FDA START Program and Strong Financials Offer Promising Outlook for Friedreich’s Ataxia Treatment Larimar Therapeutics (LRMR) is making waves in...
Vaxart’s Oral COVID-19 Vaccine Enters Phase 2b Trials: A Game-Changer in Pandemic Prevention
Sentinel Cohort Launched as Oral Vaccine Advances Towards FDA and BARDA Support Vaxart Inc. (VXRT) has announced the initiation of...
FDA Approves Bristol Myers Squibb’s Cobenfy: A Groundbreaking Schizophrenia Treatment
The First New Class of Antipsychotic Drugs in 70 Years Offers Hope for Millions but Faces Pricing Challenges In a...
EXCLUSIVE: Harmony Biosciences’ CEO, Jeffrey Dayno, on Innovation and Expanding Patient Impact
Stoxpo: Harmony Biosciences has shown strong growth with WAKIX. What factors are behind this performance? Jeffrey Dayno: Our growth is...
Weight-Loss Battle Heats Up: GLP-1 Pills Could Challenge Novo Nordisk and Eli Lilly’s Dominance
As new GLP-1 oral pills enter the market, competition rises to challenge established injectables, sparking hope and concern over side...
BCYC’s Promising Oncology Pipeline: Updates Highlight Strong Efficacy and Tolerability in Key Cancer Trials
Encouraging Data Supports Advancements in Novel Cancer Therapeutics BCYC (Bicycle Therapeutics) is continuing to make significant strides in the development...
